Summary:
Researchers at Washington University School of Medicine in St. Louis report that blocking immune cells from entering the brain preserves memory and brain tissue in a mouse model of Alzheimer’s-like tau pathology. Administering an antibody that inhibits CXCR3 reduced brain-infiltrating T cells by about half and protected roughly 40% more tissue in key memory circuits. Remarkably, these benefits occurred without the antibody crossing the blood-brain barrier and without reducing the amount of tau tangles.
Key Facts:
- Memory and tissue preserved: Mice treated with a CXCR3-blocking antibody retained approximately 40% more tissue in memory-related brain regions and performed substantially better on memory tests compared with untreated mice, despite unchanged levels of tau tangles.
- Targeting immune cell infiltration: The treatment blocks CXCR3, a receptor on activated T cells that follows the chemokine CXCL10 into the brain, reducing brain-infiltrating T cells by roughly 50%.
- No blood-brain barrier penetration required: The antibody accumulated at the brain’s border but did not enter deep brain tissue, demonstrating that modulating peripheral immune signaling can prevent neurodegeneration without crossing the blood-brain barrier.
Source: Washington University School of Medicine in St. Louis
Overview
In tauopathies such as Alzheimer’s disease, abnormal tau protein forms twisted tangles inside neurons, which are associated with progressive neuronal loss in regions responsible for memory and cognition. Growing evidence suggests that much of this damage is driven not directly by tau aggregates but by an inflammatory immune response that recruits peripheral immune cells into the brain. The new study from Washington University outlines a strategy to interrupt that immune-driven damage by blocking the pathway T cells use to enter the central nervous system.
Mechanism: Cutting Off the T-Cell Trail
Previous work from the Holtzman laboratory showed that when tau accumulates, T cells primed in peripheral lymph nodes migrate into affected brain regions and contribute to neuronal death. The new study identifies the chemokine CXCL10 and its receptor CXCR3 on T cells as the key molecular pair guiding this migration. CXCL10 levels rise in both tau-model mice and in human Alzheimer’s patients, and activated T cells expressing CXCR3 follow that chemical gradient into the brain.
Genetic removal of CXCL10 or CXCR3 prevented T cells from breaching the brain even under artificially induced inflammation. Building on those findings, the researchers treated young tau-model mice with a CXCR3-targeting antibody every five days for three and a half months. Outcomes included:
- About a 50% reduction in parenchymal T cell infiltration.
- Preservation of roughly 40% more tissue in brain regions critical for memory.
- Significantly improved performance on behavioral memory tests.
- These protective effects occurred despite identical tau tangle burden between treated and untreated groups, indicating neuroprotection independent of directly clearing tau.
Treating Brain Disease from the Outside
One major obstacle in developing therapies for neurodegenerative disease is the blood-brain barrier, which prevents many drugs from reaching the brain. The CXCR3 antibody in this study concentrated at structural border regions around the brain without entering deep parenchyma. Because it acts at the brain’s periphery to block immune cell entry, this approach avoids the need to deliver therapeutic agents across the blood-brain barrier.
Senior author David M. Holtzman, MD, emphasized that a therapy focused on reducing neurodegeneration could be transformative: “If we can show that we’re really decreasing brain cell death, it’s certainly worth trying to pursue that pathway to prevent the most devastating consequences of these diseases.” The fact that T-cell–directed therapies are already in clinical use for autoimmune diseases strengthens the rationale for exploring such strategies in Alzheimer’s and other tauopathies.
Funding and disclosures: This study received support from a BrightFocus Postdoctoral Fellowship, National Institutes of Health/National Institute on Aging grants R01AG082328 and R01AG085374, the GHR Foundation, the Carol and Gene Ludwig Initiative in Neuroimmunology Research, gifts from donors including Ronald Schaich, John Ludwig, and Cindy and Evan Goldberg, and the Freedom Together Foundation. The authors note that the content is their responsibility and may not reflect official NIH views. DMH (David M. Holtzman) co-founded and serves on the scientific advisory board of C2N Diagnostics, is on advisory boards for Denali, Genentech and Switch, and consults for Pfizer, Roche, Novartis, Annexon and Acta. DMH also serves on the advisory boards of Neuron and Cell.
Editorial Notes:
- This article was edited by a neuroscience news editor.
- The original journal paper was reviewed in full.
- Additional context was added by editorial staff.
About this Alzheimer’s disease research:
- Media Contact: Jessica Church
- Source: WUSTL (Washington University School of Medicine in St. Louis)
- Image credit: Image credited to Neuroscience News
- Original research (open access): Neuron (Sept 28, 2026). Title: “Peripheral CXCR3 blockade mitigates T cell infiltration and neurodegeneration in a mouse model of tauopathy.” Authors: Joshua T. Emmerson, Hao Hu, Vivek Savani, Rudolph E. Tanzi, Jason D. Ulrich, and David M. Holtzman.
- DOI: 10.1016/j.neuron.2026.08.030
Abstract
Peripheral CXCR3 blockade mitigates T cell infiltration and neurodegeneration in a mouse model of tauopathy
Chemokine receptor CXCR3 mediates T cell recruitment into inflamed tissues, but its role in tauopathies has been unclear. This study shows that hippocampal injection of interferon-γ (IFNγ) rapidly induces CXCL10 upregulation and triggers T cell infiltration into brain parenchyma. Genetic deletion or antibody-mediated blockade of CXCR3 prevented IFNγ-induced T cell entry. In a mouse model of tauopathy, chronic systemic anti-CXCR3 treatment markedly reduced parenchymal CD4+ and CD8+ T cell accumulation, attenuated neurodegeneration, and improved aspects of cognition.
CXCR3 blockade also decreased microglial MHC-II expression without broadly suppressing classical disease-associated inflammatory phenotypes. Single-cell RNA sequencing and flow cytometry indicated fewer activated CD4+ T cells and increased signs of terminal exhaustion among CD8+ T cells in the brain. These results identify CXCR3-dependent chemotaxis as a key pathway for T cell subtypes implicated in tau-mediated neurodegeneration and highlight peripheral CXCR3 blockade as a potential disease-modifying therapeutic approach for tauopathies.